IP Library Granted Patent US 12,240,900
Granted Patent B1
US 12,240,900 · App. 18/431,764 · Granted Mar 4, 2025

Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha

Inventor: Seah Lim (Wilmington, DE)
Assignee: MEDICOVESTOR, INC.
C07K16/28C07K2317/21C07K2317/55C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,900
App. No.
18/431,764
Granted
Mar 4, 2025
Kind
B1
Abstract

This disclosure describes nucleic acids that encode proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

Claims (26)

1. A recombinant nucleic acid, comprising:

a nucleotide sequence that encodes a protein that comprises an antigen-binding region, wherein:

the antigen-binding region comprises a first variable domain and a second variable domain;

the first variable domain comprises a VH CDR1 region including an amino acid sequence that is identical to at least 9 consecutive amino acids of SEQ ID NO: 5, a VH CDR2 region including an amino acid sequence that is identical to at least 16 consecutive amino acids of SEQ ID NO: 6, and a VH CDR3 region including an amino acid sequence that is identical to at least 10 consecutive amino acids of SEQ ID NO: 7;

the second variable domain comprises a VL CDR1 region including an amino acid sequence that is identical to at least 10 consecutive amino acids of SEQ ID NO: 8, a VL CDR2 region including an amino acid sequence that is identical to at least 6 consecutive amino acids of SEQ ID NO: 9, and a VL CDR3 region including an amino acid sequence that is identical to at least 9 consecutive amino acids of SEQ ID NO: 10; and

wherein the first variable domain and the second variable domain are paired in the antigen-binding region of the protein such that the antigen-binding region specifically binds folate receptor alpha (FRalpha).

2. The recombinant nucleic acid of claim 1 , wherein:

the first variable domain comprises the amino acid sequence that is identical to SEQ ID NO: 3; and

the second variable domain comprises the amino acid sequence that is identical to SEQ ID NO: 4.

3. The recombinant nucleic acid of claim 1 , comprising a nucleotide sequence that is at least 70 percent identical to SEQ ID NO: 1.

4. The recombinant nucleic acid of claim 1 , comprising a nucleotide sequence that encodes an amino acid sequence that is at least 90 percent identical to SEQ ID NO: 11.

5. The recombinant nucleic acid of claim 1 , comprising a nucleotide sequence that is at least 70 percent identical to SEQ ID NO: 2.

6. The recombinant nucleic acid of claim 1 , comprising a nucleotide sequence that encodes an amino acid sequence that is at least 90 percent identical to SEQ ID NO: 12.

7. The recombinant nucleic acid of claim 1 , comprising an origin of replication, wherein the recombinant nucleic acid is a plasmid.

8. A viral vector, comprising the recombinant nucleic acid of claim 1 .

9. A cell, comprising the recombinant nucleic acid of claim 7 , wherein the cell is a prokaryote.

10. A cell comprising the recombinant nucleic acid of claim 1 , wherein the cell is an immortalized mammalian cell, wherein:

the cell is a Chinese Hamster Ovary cell or a Human Embryonic Kidney cell; and

the cell expresses the protein.

11. A cell, comprising the recombinant nucleic acid of claim 1 , wherein the cell is an immortalized mammalian cell, wherein:

the cell expresses a viral vector; and

the recombinant nucleic acid comprises a packaging signal for packaging the recombinant nucleic acid in the viral vector.

12. An isolated human cell, comprising the recombinant nucleic acid of claim 1 , wherein the human cell expresses the protein.

13. The human cell of claim 12 , wherein the human cell is a human peripheral blood mononuclear cell.

14. The human cell of claim 12 , wherein the human cell is a T-cell, a natural killer cell, or a monocyte.

15. The human cell of claim 12 , wherein the protein is a chimeric antigen receptor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2024
From: LIM, SEAH
To: MEDICOVESTOR, INC.
Reel/Frame 066401/0939 →
References Cited (31)
US 5731168A · Carter · 1998 [cited by applicant]
US 5877296A · Hamann · 1999 [cited by applicant]
US 6565827B1 · Kaminski · 2003 [cited by applicant]
US 7422739B2 · Anderson · 2008 [cited by applicant]
US 7446190B2 · Sadelain · 2008 [cited by applicant]
US 7741465B1 · Eshhar · 2010 [cited by applicant]
US 8088387B2 · Steeves · 2012 [cited by applicant]
US 8277806B2 · Lindhofer · 2012 [cited by applicant]
US 8592562B2 · Kannan · 2013 [cited by applicant]
US 9499629B2 · June · 2016 [cited by applicant]
US 9505848B2 · Davis · 2016 [cited by applicant]
US 9862769B2 · De Goeij · 2018 [cited by applicant]
US 10011858B2 · Igawa · 2018 [cited by applicant]
US 10322192B2 · Albone · 2019 [cited by applicant]
US 10344050B2 · Gramer · 2019 [cited by applicant]
US 10517960B2 · Jakobsen · 2019 [cited by applicant]
US 10596270B2 · Stafford · 2020 [cited by applicant]
US 10597464B2 · Labrijn · 2020 [cited by applicant]
US 10752683B2 · Ab · 2020 [cited by applicant]
US 11597766B2 · Zugmaier · 2023 [cited by applicant]
US 20230201210A1 · Sliwkowski · 2023 [cited by applicant]
Paul, WE (1993) Fundamental Immunology, 3rd ed. Raven Press, NY, Chap. 9, pp. 292-295. [cited by examiner]
Rudikoff, S et al. (1982) Proc. Natl. Acad. Sci. USA, 79:1979-1983 (doi: 10.1073/pnas.79.6.1979). [cited by examiner]
Colman, PM (1994) Research in Immunology, Elsevier, NY, 145(1):33-36. [cited by examiner]
Bendig M. M. (1995) Methods: A Companion to Methods in Enzymology, 8:83-93. [cited by examiner]
MacCallum et al. (Oct. 11, 1996) J. Mol. Biol., 262(5):732-745. (doi: 10.1006/jmbi.1996.0548). [cited by examiner]
Casset et al (2003) Biochemical and Biophysical Research Communications, 307:198-205. (doi: 10.1016/S0006-291X(03)01131-8). [cited by examiner]
Chen et al. (1995) EMBO J., 14(12):2784-2794. (doi: 10.1002/j.1460-2075.1995.tb07278.x). [cited by examiner]
van der Neut Kolfschoten, M. et al., “Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange,” SCIENCE, Sep. 14, 2007;317(5844): 1554-7. [cited by applicant]
Shopes, B., “A genetically engineered human IgG mutant with enhanced cytolytic activity,” The Journal of Immunology, May 1, 1992;148(9):2918-22. [cited by applicant]
Shopes, B., “A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement,” Molecular Immunology, Apr. 1993;30(6):603-9. [cited by applicant]